CGT

372개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved372 programs
CGTCurated CoreFDAKiteApproved

axicabtagene ciloleucel (Yescarta, axi-cel)

LBCL, FL · CD19

#CD19#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 68Status Approved
CGTCurated CoreFDANovartisApproved

tisagenlecleucel (Kymriah, tisa-cel)

ALL, DLBCL, FL · CD19

#CD19#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 48Status Approved
CGTStandard DatabasestaleAstraZenecaPhase 2

autologous CD19-directed chimeric antigen receptor (CAR, autologous CD19-directed chimeric antigen receptor, autologous CD19-directed chimeric antigen receptor (CAR) T-cells)

Relapsed Non Hodgkin Lymphoma; Relapsed Adult ALL · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 154Status Recruiting
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 1

Anti-CD19 CAR T-cells (Anti-CD19 CAR T-cells)

B Cell Malignancies · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 92Status Recruiting
CGTStandard DatabasestaleShanghai Ming Ju Biotechnology …Phase 2

CD19-targeted Chimeric Antigen Receptor (CAR, CD19-targeted Chimeric Antigen Receptor, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)

Lymphoma, Non-Hodgkin; Diffuse Large B Cell Lymphoma · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 64Status Active
CGTLimited DatastaleTransMolecularPhase 1

Chlorotoxin (EQ, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery))

Recurrent Glioblastoma; Recurrent Malignant Glioma · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 60Status Recruiting
CGTLimited DatastaleTransMolecularPhase 1

Chlorotoxin (EQ, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery))

Recurrent Glioblastoma; Recurrent Malignant Glioma · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 60Status Recruiting
CGTStandard DatabasestaleAbClonPhase 2

Anti-CD19 Chimeric Antigen Receptor T cell (AT101, AT101(Anti-CD19 Chimeric Antigen Receptor T cell))

B-cell Non Hodgkin Lymphoma · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 59Status Recruiting
CGTAAVLimited DatastaleBayerPhase 1

AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV, AAVrh.10hFXN, serotype rh.10 adeno-associated virus, AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN)

Friedreich Ataxia; Cardiomyopathies · Friedreich Ataxia

#FriedreichAtaxia#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 58Status Recruiting
CGTStandard DatabasestaleJiangsu Topcel-KH Pharmaceutica…Phase 2

CD19 CAR T Arm (CD19 CAR T Arm)

Scleroderma, Systemic · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 56Status Recruiting
CGTLimited DatastaleNational Taiwan University Hosp…Phase 1

CD19 Chimeric Antigen Receptor (CAR, CD19 Chimeric Antigen Receptor, CD19 Chimeric Antigen Receptor (CAR) T Cells)

Relapsed/Refractory B-Cell Malignancies · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 56Status Active
CGTStandard DatabasestaleNational Cancer Institute (NCI)Phase 2

Anti-cluster of differentiation 19 (CD19, Anti-cluster of differentiation 19, Anti-cluster of differentiation 19 (CD19)-CAR PBL)

Primary Mediastinal B-cell Lymphoma; Diffuse, Large B-cell Lymphoma · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 55Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-cluster of differentiation 19 (CD19, Anti-cluster of differentiation 19, Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells)

Lymphoma, B-Cell; Lymphoma, Non-hodgkins · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 55Status Active
CGTLimited DatastaleYake Biotechnology Ltd.Phase 1

CD19/CD22 CAR T-Cells (CD19/CD22 CAR T-Cells)

Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 54Status Recruiting
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Preclinical

CD19+CD22 CAR-T (CD19+CD22 CAR-T)

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · CD19

#CD19#CGT#Preclinical#Popular#cell-gene-therapy+5
Trials 53Status Active
CGTLimited DatastaleCRISPR Therapeutics AGPhase 1

CD19-directed CAR-T cells (CD19-directed CAR-T cells)

B-cell Non-Hodgkin Lymphoma · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 53Status Active
CGTLimited DatastaleThe Leukemia and Lymphoma Socie…Phase 1

CD22 CAR (CD22 CAR)

B-ALL; B-cell Non Hodgkin Lymphoma · CD22

#CD22#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 53Status Active
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Phase 1

CD22 CAR-T (CD22 CAR-T)

Childhood Acute Lymphoblastic Leukemia · CD22

#CD22#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 53Status Active
CGTStandard DatabasestaleGenetix Biotherapeutics Inc.Phase 2

Lentiviral vector transduced CD34+ cells (Lentiviral vector transduced CD34+ cells)

P47-Phox, Deficiency of · CD3

#CD3#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 50Status Active
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

CD7 CAR T-cells (CD7 CAR T-cells)

T-cell Acute Lymphoblastic Leukemia; T-cell Acute Lymphoblastic Lymphoma · Crohn Disease

#CrohnDisease#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 49Status Active

1 / 19 pages

← PreviousNext →